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Introduction: High-dose chemotherapy supported by autologous stem cell transplantation (ASCT) continues to be a standard of care 
for relapsed diffuse large B-cell lymphoma (DLBCL) and may be considered as a frontline consolidation for a proportion of patients with 
high-risk features. Aim: We evaluated the feasibility and safety of ASCT for high-risk DLBCL who are in first complete remission after 
standard treatment with chemotherapy ± rituximab. Material and methods: A retrospective analysis of 58 patients (36 males and 22 
females) receiving up-front ASCT between 1996 and 2018 for remission consolidation. Results: Of the diagnosed, fifty patients were in 
clinical stage ≥ III. Forty-two (72%) of transplanted patients had age-adjusted IPI ≥ 2. The “B” symptoms were present in 34 patients. The 
conditioning consisted of cyclophosphamide, carmustine, etoposide (CBV) in 32 patients, carmustine, cytarabine, etoposide, melphalan 
(BEAM) in 18, and 8 patients received bendamustine, cytarabine, etoposide, melphalan (BeEAM). The transplant-related mortality was 
0% at day +30 and +100 after ASCT. Median overall survival (OS) was 4.2 years whereas progression-free survival (PFS) reached 3.0 years. 
The estimated 5-year OS and PFS were found to be 66% and 64%, respectively. The presence of “B” symptoms remained significance 
in multivariate analysis (HR 4.17 [95% CI: 1.19–14.5]; p = 0.02). No grade 3 or 4 non-hematological adverse events were observed. 
Conclusions: Up-front ASCT was found to be a safe and feasible procedure with long-term remission in approximately 70% of patients.
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Introduction
Diffuse large B-cell lymphoma non-otherwise specified (DLBCL-
NOS) is an aggressive type of B-cell non-Hodgkin lymphoma (NHL) 
that accounts for ~30% of all NHL in Western countries. DLBCL-NOS 
is more common in males than females and usually occurs in elderly 
(6th–7th decade); however, it may be observed in children and young 
adults [1, 2].
The etiology of DLBCL-NOS remains unexplained, although its 
development may be associated with exposure to prior chemotherapy 
especially in combination with radio- and/or immunotherapy. 
Moreover, risk factors include exposure to chemicals, viral infections, 
and radiation [2, 3]. Most patients present with rapidly progressing 
lymphadenopathy with strongly expressed constitutional symptoms. 
DLBCL-NOS can be demonstrated less frequently as extra-nodal 
manifestation [2, 4].
DLBCL often responds well to treatment and immune-chemotherapy 
with rituximab, cyclophosphamide, doxorubicin, vincristine, 
prednisone (R-CHOP) regimen allows to achieve complete remission 
(CR) rate in approximately 50–70% of patients [5]. High-dose 
chemotherapy supported by autologous stem cell transplantation 
(ASCT) continues to be a standard of care for relapsed setting and 
may be considered as frontline consolidation for patients having 
specific high-risk features. Though this latter indication remains 
controversial, some beneficial effects have been demonstrated [6, 7].
All patients with advanced clinical stage and/or intermediate/high-
risk and high-risk DLBCL on international prognostic index (IPI) who 
achieved CR1 after standard R-CHOP induction proceed to ASCT 
according to the transplant policy of our center. Herein, we present 
our data on safety and feasibility of ASCT in 58 consecutive patients 
transplanted during the last 22 years.
Patients and methods
A total of 58 patients (36 males and 22 females) at median age of 
49 years at diagnosis (range 18–60) received up-front ASCT between 
1996 and 2018 for remission consolidation. Fifty patients were 
diagnosed with clinical stage ≥ III. Forty-two (72%) of the transplanted 
patients had age-adjusted IPI ≥ 2. The “B” symptoms were present 
in 34 patients. A histological diagnosis of DLBCL was done by a local 
pathologist on the excised lymph node using immunochemistry. The 
disease stage was evaluated according to the Ann Arbor staging 
system and age-adjusted IPI score was calculated as published 
elsewhere [8]. The diagnostic work-up included physical examination, 
complete blood count with differential and biochemistry tests. 
Imaging studies including computed tomography (CT) of the neck, 
chest, abdomen, and pelvis and/or positron emission tomography 
(PET) were performed at diagnosis and for response assessment. 
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Bone marrow biopsy was performed at diagnosis and as needed. 
Patients were eligible for ASCT if they met the following criteria: 
(1) first complete remission after conventional immuno-chemotherapy, 
(2) advanced clinical stage [III/IV] or age-adjusted IPI ≥ 2, (3) Eastern 
Cooperative Oncology Group performance staus(ECOG) 0–2, 
(4) age < 60 years, and (5) adequate hepatic, renal, and cardiac 
function. All patients signed an informed consent. The clinical 
characteristics of patients are presented in table I.
Treatment
Induction treatment includes R-CHOP regimen (n = 50) or CHOP 
only (n = 8) and all patients studied achieved the first CR before 
ASCT. Fifty patients were transplanted during or after the year 2000. 
Peripheral blood was the source of stem cells in 50 patients (86%), 
whereas 8 subjects received bone marrow. The ifosfamide, etoposide, 
epirubicin (IVE) regimen was used for stem cell mobilization. The 
granulocyte colony stimulating factor (G-CSF) at 10 mg/kg/day was 
started from day +5 until the last day of apheresis. At least 2 × 106 
CD34-positive cells/kg were required for transplant; however, it was 
not the case in 4 patients. The apheresis product frozen to −180℃, 
stored, and re-infused after completion of conditioning was processed. 
The conditioning consisted of cyclophosphamide, carmustine, 
etoposide (CBV) in 32 patients, carmustine, cytarabine, etoposide, 
melphalan (BEAM) in 18, and 8 patients received bendamustine 
200 mg/m2, cytarabine, etoposide, melphalan (BeEAM).
Response criteria
The response to therapy was evaluated at 3 and 6 months after 
ASCT and 6 months thereafter using CT ± PET. CR was defined as 
a disappearance of all disease-related symptoms and measurable 
lesions. Relapse was defined as enlargement of initial tumor 
manifestations or occurrence of new lesions during post-ASCT 
follow-up.
Statistical methods
All calculations were made from the date of transplantation. 
Comparisons between the variables were carried out by log-rank 
test. Statistical significance was defined at a p-value <0.05. The 
probability of overall (OS) and progression-free survival (PFS) was 
calculated according to Kaplan–Meier method. Transplant-related 
mortality (TRM) was defined as death within 30 days of high-dose 
therapy and not related to the disease, relapse, and progression. 
Proportional hazards models (Cox regression) were fitted to 
investigate the effects of prognostic factors for OS. The following 
factors were entered in the model (1) patient-related: age, clinical 
Table I. Patients’ characteristics
Parameter DLBCL (n = 58)
Male/female; no 36/22
Age at diagnosis (years; median, range) 49 (18–60)
Hemoglobin level (g/dL; median, range) 12.7 (7.3–16.0)
Platelet count (×109/L; median, range) 222 (46–621)
Leukocyte count (×109/L; median, range) 6.9 (1.9–189.0)
Lymphocyte count (×109/L; median, range) 1.6 (0.1–140.0)
Monocyte count (×109/L; median, range) 0.59 (0.0–2.0)
LDH activity (IU/mL; median, range) 223 (116–939)
B2M concentration (mg/L; median, range) 2.75 (0.88–5.31)
Bone marrow involvement at diagnosis; no, % 16 (28)
Central nervous system involvement at diagnosis; no, % 1 (2)
Splenomegaly; no, % 14 (24)
Hepatomegaly; no, % 18 (31)
Number of involved nodal areas (median, range) 3 (0–7)
Number of involved extra-nodal areas (median, range) 1 (0–5)


















B symptoms; no, % 34 (59)
Rituximab containing regimen pre-ASCT; no, % 50 (86)
Radiotherapy prior ASCT; no, % 21 (36)
ASCT – autologous stem cell transplantation; B2M – beta2microglobulin; DLBCL – diffuse large B-cell lymphoma; IPI – international prognostic index; LDH – lactate dehydrogenase
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stage, age-adjusted IPI, the presence of B symptoms, hepatomegaly, 
splenomegaly, bone marrow involvement, blood parameters, use 
of rituximab, and radiotherapy; and (2) transplant-related: type of 
conditioning and date of transplant. All computations were performed 
with StatSoft Poland analysis software (version 12.0).
Results
Cell dose and engraftment
The median number of transplanted CD34-positive cells was 
4.2 × 106/kg (range 1.3–39.2). All patients engrafted. The median 
time to neutrophil recovery was 12 days (range 8–18) and platelet 
count > 20 × 109/l occurred after median of 13 days (range 5–107).
Adverse events
The most common complaints included mucositis, diarrhea, and 
infections of the upper respiratory tract. None of the patients had 
bacteremia within the first 100 days after ASCT. Grade 3 or 4 non-
hematological adverse events were not observed. All patients required 
G-CSF support during early post-transplant period.
Outcome and prognostic factors
The TRM was 0% at day +30 and +100 after ASCT. Median OS was 
4.2 years (range 0.04–21.7), whereas PFS reached 3.0 years (range 
0.04–17.8). The estimated 5-year OS and PFS were found to be 
66% and 64%, respectively (Fig. 1 and 2). A 5-year OS did not differ 
Overall survival for DLBCL after ASCT































Fig. 1. OS for DLBCL after ASCT
Progression-free survival for DLBCL after ASCT































Fig. 2. PFS for DLBCL after ASCT
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depending on the type of conditioning and was as follows: 45% vs. 
73% vs 100% for CBV, BEAM, and BeEAM, respectively (p = 0.26). 
In univariate analysis bone marrow involvement, advanced clinical 
stage and the presence of “B” symptoms were found to influence 
OS; however, only “B” symptoms remained significant in multivariate 
analysis (HR 4.17 [95% CI: 1.19–14.5]; p = 0.02) (Fig. 3). At the last 
contact, 41 (71%) patients are alive due to CR, 16 patients died of 
disease progression with subsequent chemotherapy resistance. One 
patient is alive being on salvage chemotherapy.
Discussion
High-dose chemotherapy followed by ASCT remains a standard 
therapeutic approach for relapsed/refractory chemo-sensitive 
DLBCL. An advantage of ASCT over non-rituximab conventional 
chemotherapy was demonstrated decades ago by PARMA study 
showing a significant 5-year OS benefit for transplanted patients 
when compared to those on chemotherapy only (53% vs. 32%, 
p = 0.038) [9]. The addition of rituximab to standard CHOP regimen 
was associated with substantial improvement of patients’ outcomes. 
Several randomized trials showed improved progression-free and 
overall survivals in DLBCL patients treated with R-CHOP [10, 11, 
12]. It was speculated that DLBCL may benefit from more intensive 
induction regimens, e.g. dose-adjusted etoposide, prednisone, 
vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-
EPOCH-R) when compared to R-CHOP; however, such difference 
in PFS/OS was not demonstrated. Moreover, DA-EPOCH-R was 
found to be more toxic [13]. Nevertheless, even in the rituximab era, 
the survival rates of patients being classified in high or intermediate 
IPI risk groups remained unsatisfactory [14]. In this context, ASCT 
as remission consolidation should be taken under consideration but 
its long-term benefit is to be elucidated. The potential advantage of 
ASCT as a front-line treatment for high-intermediate and high-risk 
patients on the IPI with aggressive NHL was studied in 397 patients 
who received R ± CHOP regimen as induction. After achieving 
a response, patients were randomized between ASCT (n = 125) 
and 3 additional cycles of chemotherapy (n = 128). A 2-year PFS 
was significantly better for transplant cohort when compared to non-
transplant group, 69% and 56%, respectively (p = 0.005), whereas 
OS was comparable (74% vs.71%). The results were even more 
encouraging for those at high-risk category [7]. The Italian Study 
Group enrolled 412 DLBCL patients with high-risk age-adjusted IPI. 
Two induction regimens were used before ASCT: 4 × R-CHOP14 
and 4 × R-MegaCHOP14. This treatment was followed by high-
dose chemotherapy with rituximab, cytarabine, mitoxantrone, and 
dexamethasone. BEAM conditioning was given prior to transplant. 
The patients in non-transplant arm received 8 × R-CHOP14 
and 6 × R-MegaCHOP14. It was demonstrated that patients 
randomized to transplant arm had better 3-year PFS compared to 
the non-transplant group: 70% vs. 59%; p = 0.01. No difference in 
3-year PFS was observed between induction arms (R-CHOP14 vs. 
R-Mega-CHOP14). OS was comparable between transplant and 
non-transplant group. The risk of relapse was significantly reduced 
in ASCT group [15]. It appears that ASCT as up-front treatment in 
low-risk DLBCL improves PFS and reduces relapse risk but does 
not have an impact on OS, and these findings were also confirmed 
by other study groups [16, 17]. In contrast, a Chinese study showed 
that patients who received up-front ASCT fared much better than 
the non-transplant group in terms of not only PFS but also OS [18]. 
Apart from the fact that our study was non-randomized with limited 
number of included patients, the post-transplant outcomes were 
comparable with data published elsewhere [7, 15–18]. The role of up-
front ASCT for DLBCL has been recently discussed in metaanalysis. 
The authors analyzed 4 studies with 1,173 patients and compared 
conventional chemotherapy with rituximab vs chemotherapy with 
rituximab and ASCT demonstrating no difference between two 
arms [19]. Some studies have evaluated the consolidative role 
of ASCT in DLBCL of particular high-risk groups defined by the 
presence of dual translocations (double hit lymphomas-DHL) or 
dual protein-overexpression of MYC and BCL6 (or BCL2) (double 
Kaplan-Meier survival curve






























 with B symptoms: 5-year OS=56%
 without B symptoms: 5-year OS=81%
p=0,02
Fig. 3. Survival curves depending on the presence of B symptoms
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protein-expressing lymphoma – DPL). With a median follow-up of 
127 months, there was a tendency toward better outcomes after 
ASCT for patients with DPL, but not with DHL [20]. No significant 
benefit of ASCT in the first CR for DHL was demonstrated by others 
too [21, 22].
Conditioning regimen and its impact on post-transplant outcome is of 
interest. The role of preparative regimen was analyzed in a large study 
of Spanish Cooperative Group. Briefly, two pre-transplant regimens 
were compared: chemotherapy only (BEAM, BEAC, CBV) vs. radio-
chemotherapy (cyclophosphamide with total body irradiation; [Cy/TBI]). 
A significant advantage of chemotherapy-based conditioning over 
Cy/TBI in terms of OS/RFS was demonstrated. After a median follow-
up of 28 months, OS at 8 years was significantly more favorable for 
patients treated with BEAM/BEAC vs. CBV [23]. Compared to BEAM, 
CBV regimen was associated with higher mortality in DLBCL patients 
[24]. In our study, the type of preparative regimen had no impact on 
post-transplant outcome; however, all patients on BeEAM are alive 
during the last follow-up. The latter finding requires further studies 
with larger patient population. Some prior studies have demonstrated 
the feasibility and efficacy of this conditioning for patients with 
aggressive lymphomas [25].
Several other factors may have an impact on post-transplant OS 
in DLBCL patients in remission. Bone marrow (BM) involvement, 
advanced clinical stage, and the presence of “B” symptoms influenced 
survival in univariate analysis of patients from our study; however, 
only “B” symptoms remained significant in multivariate analysis. It 
was found that bone marrow involvement is a strong adverse factor 
influencing OS/PFS in patients with DLBCL regardless of the type of 
therapy (induction immunochemotherapy with or without subsequent 
ASCT). A 3-year PFS and OS were significantly ineffective in BM-
positive vs BM-negative patients (46% vs. 73% and 65% vs. 83%, 
respectively) [26]. There was a tendency toward better outcome in BM-
negative vs BM-positive patients in our study (79% vs. 50% at 5 years; 
p = 0.06). A multivariate analysis performed by the Chinese Study 
Group revealed that the none-germinal center B cell (non-GCB) and 
IPI 3-5 negatively influenced OS [18]. Unfortunately, data on the cell 
of origin subtype were not available for our patients.
It should be noted that ASCT as a frontline treatment in patients with 
DLBCL in CR1 remained an extremely safe procedure. All side effects 
were mild and easily manageable. No death was observed in the first 
100 days after procedure; however, all patients were <60 years. The 
present study had many limitations. First, it was a non-randomized 
study and the number of treated patients was relatively small. 
Second, the data on the cell of origin subtype were not available and 
longer follow-up would be advisable.
Conclusions
In approximately 70% of transplanted patients, up-front ASCT was 
found to be a safe and feasible procedure having long-term efficacy.
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